JP2021518357A - 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法 - Google Patents

欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法 Download PDF

Info

Publication number
JP2021518357A
JP2021518357A JP2020549620A JP2020549620A JP2021518357A JP 2021518357 A JP2021518357 A JP 2021518357A JP 2020549620 A JP2020549620 A JP 2020549620A JP 2020549620 A JP2020549620 A JP 2020549620A JP 2021518357 A JP2021518357 A JP 2021518357A
Authority
JP
Japan
Prior art keywords
seq
peptide
group
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020549620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518357A5 (https=
JPWO2019178573A5 (https=
Inventor
ナタリー ウィンブレード ネアーン，
ナタリー ウィンブレード ネアーン，
スコット プレスネル，
スコット プレスネル，
クラウディア ジョハイム，
クラウディア ジョハイム，
ストラウド，　マーク
マーク ストラウド，
Original Assignee
ブレイズ バイオサイエンス， インコーポレイテッド
ブレイズ バイオサイエンス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブレイズ バイオサイエンス， インコーポレイテッド, ブレイズ バイオサイエンス， インコーポレイテッド filed Critical ブレイズ バイオサイエンス， インコーポレイテッド
Publication of JP2021518357A publication Critical patent/JP2021518357A/ja
Publication of JP2021518357A5 publication Critical patent/JP2021518357A5/ja
Publication of JPWO2019178573A5 publication Critical patent/JPWO2019178573A5/ja
Priority to JP2023203841A priority Critical patent/JP2024015145A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020549620A 2018-03-16 2019-03-15 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法 Ceased JP2021518357A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023203841A JP2024015145A (ja) 2018-03-16 2023-12-01 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862644329P 2018-03-16 2018-03-16
US62/644,329 2018-03-16
US201862676033P 2018-05-24 2018-05-24
US62/676,033 2018-05-24
PCT/US2019/022630 WO2019178573A1 (en) 2018-03-16 2019-03-15 Truncated cartilage-homing peptides and peptide complexes and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023203841A Division JP2024015145A (ja) 2018-03-16 2023-12-01 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法

Publications (3)

Publication Number Publication Date
JP2021518357A true JP2021518357A (ja) 2021-08-02
JP2021518357A5 JP2021518357A5 (https=) 2022-03-23
JPWO2019178573A5 JPWO2019178573A5 (https=) 2022-03-23

Family

ID=67906952

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020549620A Ceased JP2021518357A (ja) 2018-03-16 2019-03-15 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法
JP2023203841A Pending JP2024015145A (ja) 2018-03-16 2023-12-01 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023203841A Pending JP2024015145A (ja) 2018-03-16 2023-12-01 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法

Country Status (7)

Country Link
US (1) US20210171589A1 (https=)
EP (1) EP3773668A4 (https=)
JP (2) JP2021518357A (https=)
CN (1) CN112105375A (https=)
AU (1) AU2019233914A1 (https=)
CA (1) CA3093588A1 (https=)
WO (1) WO2019178573A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4031162A1 (en) * 2019-09-20 2022-07-27 Zealand Pharma A/S Kv1.3 blockers
JP2024503480A (ja) * 2021-01-19 2024-01-25 ウィリアム マーシュ ライス ユニバーシティ ポリペプチドの骨特異的送達法
CN116206697B (zh) * 2023-01-18 2025-07-15 北京石油化工学院 共晶配体筛选方法和系统

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009023993A (ja) * 2007-06-19 2009-02-05 Okayama Univ 軟骨マーカー
JP2010505444A (ja) * 2006-10-10 2010-02-25 エコレ ポルイテクフニクエ フェデラレ デ ラウサンネ 軟骨にターゲティングするためのポリペプチドリガンド及びその使用方法
WO2014093406A1 (en) * 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Methods for screening
WO2015075699A1 (en) * 2013-11-25 2015-05-28 Sanofi Dotam derivatives for therapeutic use
WO2017044894A2 (en) * 2015-09-09 2017-03-16 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
WO2017100700A2 (en) * 2015-12-11 2017-06-15 Fred Hutchinson Cancer Research Center Peptides for renal therapy
WO2018049285A1 (en) * 2016-09-09 2018-03-15 Fred Hutchinson Cancer Research Center Stable peptides and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2981821B2 (en) * 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
CN107405388A (zh) * 2015-01-08 2017-11-28 衣阿华大学研究基金会 用于体内关节软骨再生的方法
EP3595699A4 (en) * 2017-03-16 2020-12-23 Blaze Bioscience, Inc. PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
AU2018283161A1 (en) * 2017-06-15 2020-01-02 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505444A (ja) * 2006-10-10 2010-02-25 エコレ ポルイテクフニクエ フェデラレ デ ラウサンネ 軟骨にターゲティングするためのポリペプチドリガンド及びその使用方法
JP2009023993A (ja) * 2007-06-19 2009-02-05 Okayama Univ 軟骨マーカー
WO2014093406A1 (en) * 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Methods for screening
WO2015075699A1 (en) * 2013-11-25 2015-05-28 Sanofi Dotam derivatives for therapeutic use
WO2017044894A2 (en) * 2015-09-09 2017-03-16 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
WO2017100700A2 (en) * 2015-12-11 2017-06-15 Fred Hutchinson Cancer Research Center Peptides for renal therapy
WO2018049285A1 (en) * 2016-09-09 2018-03-15 Fred Hutchinson Cancer Research Center Stable peptides and methods of use thereof

Also Published As

Publication number Publication date
AU2019233914A1 (en) 2020-09-24
EP3773668A4 (en) 2022-10-19
US20210171589A1 (en) 2021-06-10
WO2019178573A1 (en) 2019-09-19
EP3773668A1 (en) 2021-02-17
JP2024015145A (ja) 2024-02-01
CN112105375A (zh) 2020-12-18
CA3093588A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
US11648290B2 (en) Cartilage-homing peptides
JP7280193B2 (ja) 軟骨ホーミングペプチドコンジュゲート及びその使用方法
US11331393B2 (en) Renal-homing peptide conjugates and methods of use thereof
US12048750B2 (en) Tissue-homing peptide conjugates and methods of use thereof
JP2024015145A (ja) 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法
JP2024019603A (ja) 軟骨ホーミングペプチドの複合体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231207

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240222

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240621